<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERY-PED- erythromycin ethylsuccinate suspension </strong><br>Arbor Pharmaceuticals, Inc.<br></p></div>
<h1>ERY-PED<span class="Sup">®</span><br> (ERYTHROMYCIN<br> ETHYLSUCCINATE, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Erythromycin is produced by a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of<span class="Italics"> Saccharopolyspora erythraea </span>(formerly<span class="Italics"> Streptomyces erythraeus</span>) and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. The base, the stearate salt, and the esters are poorly soluble in water. Erythromycin ethylsuccinate is an ester of erythromycin suitable for oral administration. Erythromycin ethylsuccinate is known chemically as erythromycin 2'-(ethyl succinate). The molecular formula is C<span class="Sub">43</span>H<span class="Sub">75</span>NO<span class="Sub">16</span> and the molecular weight is 862.06. The structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04775721-ab87-4b66-808c-d67a21032385&amp;name=eryped-01.jpg"></div>
<p>Ery-Ped 200 (erythromycin ethylsuccinate for oral suspension) when reconstituted with water, forms a suspension containing erythromycin ethylsuccinate equivalent to 200 mg erythromycin per 5 mL (teaspoonful) or 100 mg per 2.5 mL (dropperful) with an appealing fruit flavor. Ery-Ped 400 when reconstituted with water, forms a suspension containing erythromycin ethylsuccinate equivalent to 400 mg of erythromycin per 5 mL (teaspoonful) with an appealing banana flavor.</p>
<p>These products are intended primarily for pediatric use but can also be used in adults.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>Inactive Ingredients</h2>
<p class="First">Ery-Ped 200, Ery-Ped 400:</p>
<p>Caramel, polysorbate, sodium citrate, sucrose, xanthan gum and artificial flavors.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed under both fasting and nonfasting conditions.</p>
<p>Erythromycin diffuses readily into most body fluids. Only low concentrations are normally achieved in the spinal fluid, but passage of the drug across the blood-brain barrier increases in <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. In the presence of normal hepatic function, erythromycin is concentrated in the liver and excreted in the bile; the effect of hepatic dysfunction on excretion of erythromycin by the liver into the bile is not known. Less than 5 percent of the orally administered dose of erythromycin is excreted in active form in the urine.</p>
<p>Erythromycin crosses the placental barrier, but fetal plasma levels are low. The drug is excreted in human milk.</p>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Erythromycin acts by inhibition of protein synthesis by binding 50<span class="Italics"> S </span>ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Antagonism has been demonstrated<span class="Italics"> in vitro </span>between erythromycin and clindamycin, lincomycin, and chloramphenicol.</p>
<p>Many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of<span class="Italics"> Haemophilus influenzae </span>are resistant to erythromycin alone but are susceptible to erythromycin and sulfonamides used concomitantly.</p>
<p>Staphylococci resistant to erythromycin may emerge during a course of therapy.</p>
<p>Erythromycin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both<span class="Italics"> in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the<span class="Bold"> INDICATIONS AND USAGE </span>section.</p>
<p><span class="Bold">Gram-positive Organisms:</span></p>
<dl>
<dt> </dt>
<dd><span class="Italics">Corynebacterium diphtheriae</span></dd>
<dt> </dt>
<dd><span class="Italics">Corynebacterium minutissimum</span></dd>
<dt> </dt>
<dd><span class="Italics">Listeria monocytogenes</span></dd>
<dt> </dt>
<dd>
<span class="Italics">Staphylococcus aureus </span>(resistant organisms may emerge during treatment)</dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus pneumoniae</span></dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus pyogenes</span></dd>
</dl>
<p><span class="Bold">Gram-negative Organisms:</span></p>
<dl>
<dt> </dt>
<dd><span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span></dd>
<dt> </dt>
<dd><span class="Italics">Legionella pneumophila</span></dd>
<dt> </dt>
<dd><span class="Italics">Neisseria gonorrhoeae</span></dd>
</dl>
<p><span class="Bold">Other Microorganisms:</span></p>
<dl>
<dt> </dt>
<dd><span class="Italics">Chlamydia trachomatis</span></dd>
<dt> </dt>
<dd><span class="Italics">Entamoeba histolytica</span></dd>
<dt> </dt>
<dd><span class="Italics">Mycoplasma pneumoniae</span></dd>
<dt> </dt>
<dd><span class="Italics">Treponema pallidum</span></dd>
<dt> </dt>
<dd><span class="Italics">Ureaplasma urealyticum</span></dd>
</dl>
<p>The following<span class="Italics"> in vitro </span>data are available.</p>
<p>Erythromycin exhibits<span class="Italics"> in vitro </span>minimal inhibitory concentrations (MIC's) of 0.5 µg/mL or less against most (≥ 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of erythromycin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
<p><span class="Bold">Gram-positive Organisms:</span></p>
<dl>
<dt> </dt>
<dd>Viridans group streptococci</dd>
</dl>
<p><span class="Bold">Gram-negative Organisms:</span></p>
<dl>
<dt> </dt>
<dd><span class="Italics">Moraxella catarrhalis</span></dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>Susceptibility Tests</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1.1"></a><p></p>
<h4>Dilution Techniques</h4>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC's). These MIC's provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC's should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1,2</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of erythromycin powder. The MIC values should be interpreted according to the following criteria:</p>
<p><span class="Bold">For Staphylococcus spp</span></p>
<table width="50%">
<col align="center" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th align="left">MIC (µg/mL)</th>
<th align="left">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≤ 0.5</td>
<td align="left">Susceptible (S)</td>
</tr>
<tr>
<td align="center">1 - 4</td>
<td align="left">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≥ 8</td>
<td align="left">Resistant (R)</td>
</tr>
</tbody>
</table>
<p><span class="Bold">For Streptococcus spp. and Streptococcus pneumoniae:</span></p>
<table width="50%">
<col align="center" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th align="left">MIC (µg/mL)</th>
<th align="left">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≤ 0.25</td>
<td align="left">Susceptible (S)</td>
</tr>
<tr>
<td align="center">0.5</td>
<td align="left">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≥ 1</td>
<td align="left">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard erythromycin powder should provide the following MIC values:</p>
<table width="50%">
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="40%">
<thead><tr class="First Last">
<th align="left">Microorganism</th>
<th align="center">MIC (µg/mL)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>ATCC is a registered trademark of the American Type Culture Collection</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">
<span class="Italics">S. aureus </span>ATCC<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> 29213</td>
<td align="center">0.25-1</td>
</tr>
<tr>
<td align="left">
<span class="Italics">E. faecalis </span>ATCC 29212</td>
<td align="center">1-4</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">S. pneumoniae </span>ATCC 49619</td>
<td align="center">0.03-0.12</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1.2"></a><p></p>
<h4>Diffusion Techniques</h4>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 15-µg erythromycin to test the susceptibility of microorganisms to erythromycin.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 15-µg erythromycin disk should be interpreted according to the following criteria:</p>
<p><span class="Bold">For Staphylococcus spp:</span></p>
<table width="50%">
<col align="center" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th align="left">Zone Diameter (mm)</th>
<th align="left">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≥ 23</td>
<td align="left">Susceptible (S)</td>
</tr>
<tr>
<td align="center">14 - 22</td>
<td align="left">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≤ 13</td>
<td align="left">Resistant (R)</td>
</tr>
</tbody>
</table>
<p><span class="Bold">For Streptococcus spp. and Streptococcus pneumoniae:</span></p>
<table width="50%">
<col align="center" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th align="left">Zone Diameter (mm)</th>
<th align="left">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≥ 21</td>
<td align="left">Susceptible (S)</td>
</tr>
<tr>
<td align="center">16 - 20</td>
<td align="left">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≤ 15</td>
<td align="left">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for erythromycin.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 15-µg erythromycin disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<table width="50%">
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="40%">
<thead><tr class="First Last">
<th align="left">Microorganism</th>
<th align="center">Zone Diameter (mm)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">
<span class="Italics">S. aureus </span>ATCC 25923</td>
<td align="center">22-30</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">S. pneumoniae</span> ATCC 49619</td>
<td align="center">25-30</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="IU"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Ery-Ped is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms in the diseases listed below:</p>
<p><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span> of mild to moderate degree caused by<span class="Italics"> Streptococcus pyogenes, Streptococcus pneumoniae, </span>or<span class="Italics"> Haemophilus influenzae</span> (when used concomitantly with adequate doses of sulfonamides, since many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae </span>are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.)</p>
<p>Lower-<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span> of mild to moderate severity caused by<span class="Italics"> Streptococcus pneumoniae </span>or<span class="Italics"> Streptococcus pyogenes</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">Listeriosis</span> caused by <span class="Italics">Listeria monocytogenes</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> (whooping <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>) caused by <span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span>. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> in exposed susceptible individuals.</p>
<p><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> due to<span class="Italics"> Mycoplasma pneumoniae</span>.</p>
<p>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of mild to moderate severity caused by<span class="Italics"> Streptococcus pyogenes </span>or<span class="Italics"> Staphylococcus aureus </span>(resistant staphylococci may emerge during treatment).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> due to<span class="Italics"> Corynebacterium diphtheriae</span>, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Erythrasma</h2>
<p class="First">In the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to<span class="Italics"> Corynebacterium minutissimum</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<p class="First">Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> caused by<span class="Italics"> Entamoeba histolytica</span> (oral erythromycins only). Extraenteric <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> requires treatment with other agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">Pelvic Inflammatory Disease</span> Caused by<span class="Italics"> Neisseria gonorrhoeae</span>
</h2>
<p class="First"> As an alternative drug in treatment of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by <span class="Italics">N. gonorrhoeae </span>in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> before receiving erythromycin as treatment of <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> and a follow-up serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> after 3 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> Caused by<span class="Italics"> Treponema pallidum</span>
</h2>
<p class="First">Erythromycin is an alternate choice of treatment for primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> in penicillin-allergic patients. In primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6"></a><p></p>
<h2>Erythromycins are indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by<span class="Italics"> Chlamydia trachomatis</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span> of the newborn, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> of infancy, and urogenital <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults due to<span class="Italics"> Chlamydia trachomatis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7"></a><p></p>
<h2></h2>
<p class="First">When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by <span class="Italics">Ureaplasma urealyticum</span>.</p>
<p>Legionnaires' Disease caused by<span class="Italics"> Legionella pneumophila</span>. Although no controlled clinical efficacy studies have been conducted, <span class="Italics">in vitro </span>and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.8"></a><p></p>
<h2>Prophylaxis</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.8.1"></a><p></p>
<h3>Prevention of Initial Attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span></h3>
<p class="First">Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> (treatment of<span class="Italics"> Streptococcus pyogenes </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the upper respiratory tract, e.g., <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>). Erythromycin is indicated for the treatment of penicillin-allergic patients.<span class="Sup">4</span> The therapeutic dose should be administered for 10 days.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.8.2"></a><p></p>
<h3>Prevention of Recurrent Attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span></h3>
<p class="First">Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">Streptococcal pharyngitis</span> (for the prevention of recurrent attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>).<span class="Sup">4</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Erythromycin is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this antibiotic.</p>
<p>Erythromycin is contraindicated in patients taking terfenadine, astemizole, pimozide, or cisapride. (See<span class="Bold"><a href="#DI"> PRECAUTIONS - Drug Interactions</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, occurring in patients receiving oral erythromycin products.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>QT Prolongation</h2>
<p class="First">Erythromycin has been associated with prolongation of the QT interval and infrequent cases of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> have been spontaneously reported during postmarketing surveillance in patients receiving erythromycin. Fatalities have been reported. Erythromycin should be avoided in patients with known prolongation of the QT interval, patients with ongoing proarrhythmic conditions such as uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> in Pregnancy</h2>
<p class="First">There have been reports suggesting that erythromycin does not reach the fetus in adequate concentration to prevent <span class="product-label-link" type="condition" conceptid="434279" conceptname="Congenital syphilis">congenital syphilis</span>. Infants born to women treated during pregnancy with oral erythromycin for early <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> should be treated with an appropriate penicillin regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2>Clostridium difficile Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Ery-Ped, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Serious adverse reactions have been reported in patients taking erythromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with simvastatin, lovastatin, and atorvastatin; and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with calcium channel blockers metabolized by CYP3A4 (e.g. verapamil, amlodipine, diltiazem) (see<span class="Bold"><a href="#DI"> PRECAUTIONS – Drug Interactions</a></span>).</p>
<p>There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine. This interaction is potentially life-threatening, and may occur while using both drugs at their recommended doses (see<span class="Bold"><a href="#DI"> PRECAUTIONS – Drug Interactions</a></span>).</p>
<p><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> with or without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin. Therefore, patients receiving concomitant lovastatin and erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels. (See package insert for lovastatin)</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing Ery-Ped in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Since erythromycin is principally excreted by the liver, caution should be exercised when erythromycin is administered to patients with impaired hepatic function. (See<span class="Bold"><a href="#CP"> CLINICAL PHARMACOLOGY </a></span>and<span class="Bold"><a href="#WARNINGS"> WARNINGS </a></span>sections.)</p>
<p>Exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> and new onset of symptoms of <span class="product-label-link" type="condition" conceptid="4237155" conceptname="Eaton-Lambert syndrome">myasthenic syndrome</span> has been reported in patients receiving erythromycin therapy.</p>
<p>There have been reports of infantile hypertrophic <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span> (IHPS) occurring in infants following erythromycin therapy. In one cohort of 157 newborns who were given erythromycin for <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> prophylaxis, seven neonates (5%) developed symptoms of non-<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">bilious vomiting</span> or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> with feeding and were subsequently diagnosed as having IHPS requiring surgical<span class="Italics"> pyloromyotomy</span>. A possible dose-response effect was described with an absolute risk of IHPS of 5.1% for infants who took erythromycin for 8-14 days and 10% for infants who took erythromycin for 15-21 days.<span class="Sup">5</span> Since erythromycin may be used in the treatment of conditions in infants which are associated with significant mortality or morbidity (such as <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> or neonatal <span class="Italics">Chlamydia trachomatis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>), the benefit of erythromycin therapy needs to be weighed against the potential risk of developing IHPS. Parents should be informed to contact their physician if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> with feeding occurs.</p>
<p>Prolonged or repeated use of erythromycin may result in an overgrowth of nonsusceptible bacteria or fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, erythromycin should be discontinued and appropriate therapy instituted.</p>
<p>When indicated, incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy. Observational studies in humans have reported cardiovascular malformations after exposure to drug products containing erythromycin during early pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including Ery-Ped should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Ery-Ped is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Ery-Ped or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DI"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3>Theophylline</h3>
<p class="First">Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.</p>
<p>There have been published reports suggesting that when oral erythromycin is given concurrently with theophylline there is a decrease in erythromycin serum concentrations of approximately 35%. The mechanism by which this interaction occurs is unknown. The decrease in erythromycin concentrations due to co-administration of theophylline could result in subtherapeutic concentrations of erythromycin.</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> have been observed in patients receiving concurrent verapamil, belonging to the calcium channel blockers drug class.</p>
<p>Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.</p>
<p>There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with various oral anticoagulants may be more pronounced in the elderly.</p>
<p>Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme system (CYP3A). Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving erythromycin.</p>
<p>The following are examples of some clinically significant CYP3A based drug interactions. Interactions with other drugs metabolized by the CYP3A isoform are also possible. The following CYP3A based drug interactions have been observed with erythromycin products in post-marketing experience:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1.1"></a><p></p>
<h4>Ergotamine/dihydroergotamine</h4>
<p class="First">Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities and other tissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or dihydroergotamine is contraindicated (see<span class="Bold"><a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1.2"></a><p></p>
<h4>Triazolobenzodiazepines (such as triazolam and alprazolam) and Related Benzodiazepines</h4>
<p class="First">Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1.3"></a><p></p>
<h4>HMG-CoA Reductase Inhibitors</h4>
<p class="First">Erythromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors (e.g., lovastatin and simvastatin). Rare reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients taking these drugs concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1.4"></a><p></p>
<h4>Sildenafil (Viagra)</h4>
<p class="First">Erythromycin has been reported to increase the systemic exposure (AUC) of sildenafil. Reduction of sildenafil dosage should be considered. (See Viagra package insert.)</p>
<p>There have been spontaneous or published reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine, and bromocriptine.</p>
<p>Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated. (See<span class="Bold"><a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a></span>.)</p>
<p>In addition, there have been reports of interactions of erythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.</p>
<p>Erythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QT<span class="Sub">c</span> interval prolongation, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, and other <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> have been observed. (See<span class="Bold"><a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a></span>.) In addition, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported rarely with concomitant administration of terfenadine and erythromycin.</p>
<p>There have been post-marketing reports of drug interactions when erythromycin was co-administered with cisapride, resulting in QT prolongation, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> most likely due to the inhibition of hepatic metabolism of cisapride by erythromycin. Fatalities have been reported. (See<span class="Bold"><a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1.5"></a><p></p>
<h4>Colchicine</h4>
<p class="First">Colchicine is a substrate for both CYP3A4 and the efflux transporter P-glycoprotein (P-gp). Erythromycin is considered a moderate inhibitor of CYP3A4. A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin. If co-administration of colchicine and erythromycin is necessary, the starting dose of colchicine may need to be reduced, and the maximum colchicine dose should be lowered. Patients should be monitored for clinical symptoms of colchicine toxicity (see<span class="Bold"><a href="#WARNINGS"> WARNINGS</a></span>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Erythromycin interferes with the fluorometric determination of urinary catecholamines.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term oral dietary studies conducted with erythromycin stearate in rats up to 400 mg/kg/day and in mice up to 500 mg/kg/day (approximately 1-2 fold of the maximum human dose on a body surface area basis) did not provide evidence of tumorigenicity. Erythromycin stearate did not show genotoxic potential in the Ames, and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assays or induce chromosomal aberrations in CHO cells. There was no apparent effect on male or female fertility in rats treated with erythromycin base by oral gavage at 700 mg/kg/day (approximately 3 times the maximum human dose on a body surface area basis).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">There is no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or any other adverse effect on reproduction in female rats fed erythromycin base by oral gavage at 350 mg/kg/day (approximately twice the maximum recommended human dose on a body surface area) prior to and during mating, during gestation, and through weaning. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or embryotoxicity was observed when erythromycin base was given by oral gavage to pregnant rats and mice at 700 mg/kg/day and to pregnant rabbits at 125 mg/kg/day (approximately 1-3 times the maximum recommended human dose).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effect of erythromycin on labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Erythromycin is excreted in human milk. Caution should be exercised when erythromycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See<span class="Bold"><a href="#IU"> INDICATIONS AND USAGE </a></span>and<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION </a></span>sections.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Elderly patients, particularly those with reduced renal or hepatic function, may be at increased risk for developing erythromycin-induced <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>. (See<span class="Bold"><a href="#AR"> ADVERSE REACTIONS </a></span>and<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>Elderly patients may be more susceptible to development of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> than younger patients. (See<span class="Bold"><a href="#WARNINGS"> WARNINGS</a></span>).</p>
<p>Elderly patients may experience increased effects of oral anticoagulant therapy while undergoing treatment with erythromycin. (See<span class="Bold"><a href="#DI"> PRECAUTIONS - Drug Interactions</a></span>).</p>
<p>Ery-Ped 200 contains 117.5 mg (5.1 mEq) of sodium per individual dose.</p>
<p>Ery-Ped 400 contains 117.5 mg (5.1 mEq) of sodium per individual dose.</p>
<p>Based on the 200 mg/5 mL strength, at the usual recommended doses, adult patients would receive a total of 940 mg/day (40.8 mEq) of sodium. Based on the 400 mg/5 mL strength, at the usual recommended doses, adult patients would receive a total of 470 mg/day (20.4 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. They include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. Symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, hepatic dysfunction and/or abnormal liver function test results may occur. (See<span class="Bold"><a href="#WARNINGS"> WARNINGS </a></span>section.)</p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment. (See<span class="Bold"><a href="#WARNINGS"> WARNINGS</a></span>.)</p>
<p>Erythromycin has been associated with QT prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>. (See<span class="Bold"><a href="#WARNINGS"> WARNINGS</a></span>.)</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> ranging from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have occurred. <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span> ranging from mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span> to <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported rarely.</p>
<p>There have been reports of interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> coincident with erythromycin use.</p>
<p>There have been rare reports of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>There have been isolated reports of reversible <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> occurring chiefly in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and in patients receiving high doses of erythromycin.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In case of overdosage, erythromycin should be discontinued. Overdosage should be handled with the prompt elimination of unabsorbed drug and all other appropriate measures should be instituted.</p>
<p>Erythromycin is not removed by peritoneal dialysis or hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Ery-Ped (erythromycin ethylsuccinate) oral suspensions may be administered without regard to meals.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Children</h2>
<p class="First">Age, weight, and severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> are important factors in determining the proper dosage. In mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the usual dosage of erythromycin ethylsuccinate for children is 30 to 50 mg/kg/day in equally divided doses every 6 hours. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> this dosage may be doubled. If twice-a-day dosage is desired, one-half of the total daily dose may be given every 12 hours. Doses may also be given three times daily by administering one-third of the total daily dose every 8 hours.</p>
<p>The following dosage schedule is suggested for mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<table width="60%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th align="left">Body Weight</th>
<th align="left">Total Daily Dose</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td align="left">Under 10 lbs</td>
<td align="left">30-50 mg/kg/day<br>15-25 mg/lb/day</td>
</tr>
<tr class="Botrule">
<td align="left">10 to 15 lbs</td>
<td align="left">200 mg</td>
</tr>
<tr class="Botrule">
<td align="left">16 to 25 lbs</td>
<td align="left">400 mg</td>
</tr>
<tr class="Botrule">
<td align="left">26 to 50 lbs</td>
<td align="left">800 mg</td>
</tr>
<tr class="Botrule">
<td align="left">51 to 100 lbs</td>
<td align="left">1200 mg</td>
</tr>
<tr class="Last">
<td align="left">over 100 lbs</td>
<td align="left">1600 mg</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Adults</h2>
<p class="First">400 mg erythromycin ethylsuccinate every 6 hours is the usual dose. Dosage may be increased up to 4 g per day according to the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If twice-a-day dosage is desired, one-half of the total daily dose may be given every 12 hours. Doses may also be given three times daily by administering one-third of the total daily dose every 8 hours.</p>
<p>For adult dosage calculation, use a ratio of 400 mg of erythromycin activity as the ethylsuccinate to 250 mg of erythromycin activity as the stearate, base or estolate.</p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, a therapeutic dosage of erythromycin ethylsuccinate should be administered for at least 10 days. In continuous prophylaxis against recurrences of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span> in persons with a history of rheumatic heart disease, the usual dosage is 400 mg twice a day.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.1"></a><p></p>
<p class="First"><span class="Bold">For treatment of <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> due to <span class="Italics">C. trachomatis</span> or <span class="Italics">U. urealyticum</span></span></p>
<p>800 mg three times a day for 7 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.2"></a><p></p>
<p class="First"><span class="Bold">For treatment of primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.2.1"></a><p></p>
<h4>Adults</h4>
<p class="First">48 to 64 g given in divided doses over a period of 10 to 15 days</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.3"></a><p></p>
<p class="First"><span class="Bold">For intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.3.1"></a><p></p>
<h4>Adults</h4>
<p class="First">400 mg four times daily for 10 to 14 days. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.3.2"></a><p></p>
<h4>Children</h4>
<p class="First">30 to 50 mg/kg/day in divided doses for 10 to 14 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.4"></a><p></p>
<p class="First"><span class="Bold">For use in <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span></p>
<p>Although optimal dosage and duration have not been established, doses of erythromycin utilized in reported clinical studies were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.5"></a><p></p>
<p class="First"><span class="Bold">For treatment of Legionnaires' Disease</span></p>
<p>Although optimal doses have not been established, doses utilized in reported clinical data were 1.6 to 4 g daily in divided doses.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Ery-Ped 200 (erythromycin ethylsuccinate for oral suspension, USP) is supplied in bottles of 100 mL (<span class="Bold">NDC </span>24338-132-13)</p>
<p>Ery-Ped 400 (erythromycin ethylsuccinate for oral suspension, USP) is supplied in bottles of 100 mL (<span class="Bold">NDC </span>24338-130-13)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2>Recommended Storage</h2>
<p class="First">Store Ery-Ped 200 and Ery-Ped 400, prior to mixing, below 86°F (30°C). After reconstitution, Ery-Ped 200 and Ery-Ped 400 must be stored at or below 77°F (25°C) and used within 35 days; refrigeration is not required.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute.<span class="Italics"> Method for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</span>, 7th ed. Approved Standard CLSI Document M07-A7, Vol. 26(2). CLSI, Wayne, PA, Jan. 2006.</li>
<li>Clinical and Laboratory Standards Institute. <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing, 18th Informational Supplement</span>, CLSI Document M100-S18, Vol 28(1). CLSI, Wayne, PA, Jan. 2008.</li>
<li>Clinical and Laboratory Standards Institute.<span class="Italics"> Performance Standards for Antimicrobial Disk Susceptibility Tests</span>, 9th ed. Approved Standard CLSI Document M02-A9, Vol. 26(1). CLSI, Wayne, PA, Jan. 2006.</li>
<li>Committee on <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association: Prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>. Circulation. 78(4):1082-1086, October 1988.</li>
<li>Honein, M.A., et. al.: Infantile hypertrophic <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span> after <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> prophylaxis with erythromycin: a case review and cohort study. The Lancet 1999;354 (9196): 2101-5</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">Revised: June, 2012 03-A611-R1</p>
<p>Arbor Pharmaceuticals, Inc.<br>Atlanta, GA 30328</p>
<p><span class="Bold">arbor<span class="Sup">®</span></span><br>PHARMACEUTICALS, INC.</p>
<p>(Nos. 6302, 6305)<br> 03-A611-R1-Rev. June, 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 200 mg per 5 mL Bottle Label</h1>
<p class="First"><span class="Bold">NDC </span>24338-132-13<br><span class="Bold">100 mL For Oral Suspension</span><br>(when mixed)</p>
<p><span class="Bold">EryPed</span><span class="Sup">®</span><span class="Bold"> 200</span></p>
<p>ERYTHROMYCIN<br>ETHYLSUCCINATE FOR<br>ORAL SUSPENSION, USP</p>
<p><span class="Bold">Erythromycin activity</span></p>
<p><span class="Bold">200 mg per 5 mL</span><br>when reconstituted</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">arbor</span><span class="Sup">®</span><br>PHARMACEUTICALS, INC.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 200 mg per 5 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04775721-ab87-4b66-808c-d67a21032385&amp;name=eryped-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 400 mg per 5 mL Bottle Label</h1>
<p class="First"><span class="Bold">NDC </span>24338-130-13<br><span class="Bold">100 mL For Oral Suspension</span><br>(when mixed)</p>
<p><span class="Bold">EryPed</span><span class="Sup">®</span><span class="Bold"> 400</span></p>
<p>ERYTHROMYCIN<br>ETHYLSUCCINATE FOR<br>ORAL SUSPENSION, USP</p>
<p><span class="Bold">Erythromycin activity</span></p>
<p><span class="Bold">400 mg per 5 mL</span><br>when reconstituted</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">arbor</span><span class="Sup">®</span><br>PHARMACEUTICALS, INC.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 400 mg per 5 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04775721-ab87-4b66-808c-d67a21032385&amp;name=eryped-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERY-PED 		
					</strong><br><span class="contentTableReg">erythromycin ethylsuccinate suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24338-132</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Erythromycin Ethylsuccinate</strong> (Erythromycin) </td>
<td class="formItem">Erythromycin</td>
<td class="formItem">200 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Caramel</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24338-132-13</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050207</td>
<td class="formItem">07/05/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERY-PED 		
					</strong><br><span class="contentTableReg">erythromycin ethylsuccinate suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24338-130</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Erythromycin Ethylsuccinate</strong> (Erythromycin) </td>
<td class="formItem">Erythromycin</td>
<td class="formItem">400 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Caramel</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24338-130-13</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050207</td>
<td class="formItem">06/14/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Arbor Pharmaceuticals, Inc.
							(781796417)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>97846f49-4484-46c0-9093-ceaaa1a81cc8</div>
<div>Set id: 04775721-ab87-4b66-808c-d67a21032385</div>
<div>Version: 5</div>
<div>Effective Time: 20130814</div>
</div>
</div> <div class="DistributorName">Arbor Pharmaceuticals, Inc.</div></p>
</body></html>
